A selective estrogen receptor modulator for the treatment of hot flushes

Journal of Medicinal Chemistry

Volumn 49, Issue 3, 2006, Pages 843-846

  Wallace, Owen B ^a   Lauwers, Kenneth S ^a   Dodge, Jeffrey A ^a   May, Scott A ^a   Calvin, Joel R ^a   Hinklin, Ronald ^b   Bryant, Henry U ^a   Shetler, Pamela K ^a   Adrian, Mary D ^a   Geiser, Andrew G ^a   Sato, Masahiko ^a   Burris, Thomas P ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; 7,9 DIFLUORO 5 [4 (2 PIPERIDIN 1 YLETHOXY)PHENYL] 5H 6 OXCHRYSEN 2 OL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA ANTAGONIST; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA ANTAGONIST; LSN 2120310; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BREAST ADENOCARCINOMA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; ESTROGEN BINDING; HOT FLUSH; IN VIVO STUDY; MENOPAUSE; NONHUMAN; OVARIECTOMY; RAT; THERMOREGULATION; UTERUS CANCER;

ADENOCARCINOMA; ANIMALS; ANTICHOLESTEREMIC AGENTS; BENZOPYRANS; BONE DENSITY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLESTEROL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HOT FLASHES; HUMANS; MORPHINE; NAPHTHALENES; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STEREOISOMERISM; UTERINE NEOPLASMS; UTERUS;

EID: 32344433109     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0509795     Document Type: Article

References (24)

1. Neugarten, B. L.; Kraines, R. J. Menopausal symptoms in women of various ages. Psychosom. Med. 1965, 27, 266-273.
2. Jaszmann, L.; Van Lith, N. D.; Zaat, J. C. A. The perimenopausal symptoms: The statistical analysis of a survey. Med Gynecol. Socio. 1969, 4, 268-277.
3. Kronenberg, F.; Downey, J. A. Thermoregulatory physiology of menopausal hot flashes: a review. Can. J. Physiol. Pharmacol. 1987, 65, 1312-1324.
4. Shanafelt, T. D.; Barton, D. L.; Adjei, A. A.; Loprinzi, C. L. Pathophysiology and treatment of hot flushes. Mayo Clin. Proc. 2002, 77, 1207-1218.
5. Love, R. R.; Cameron, L.; Connell, B. L.; Leventhal, H. Arch. Intern. Med. 1991, 151, 1842-1847.
6. Draper, M. W.; Flowers, D. E.; Huster, W. J.; Neild, J. A.; Harper, K. D.; Arnaud, C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy post-menopausal women. J. Bone Miner. Res. 1996, 11, 835-842.
7. (b) Walsh, B. W.; Kuller, L. H.; Wild, R. A.; Paul, S.; Farmer, M.; Lawrence, J. B.; Shah, A. S.; Anderson, P. W. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J. Am. Med. Assoc. 1998, 279, 1445-1451.
8. Hulley, S.; Grady, D.; Bush, T.; Furberg, C.; Herrington, D.; Riggs, B.; Vittinghoff, E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 1998, 280, 605-613.
9. Coope, J.; March, J. Can we improve compliance with long-term HRT? Maturitas 1992, 15, 151-158.
10. Watanabe, N.; Ikeno, A.; Minato, H.; Nakagawa, H.; Kohayakawa, C.; Tsuji, J-i. Discovery and preclinical characterization of (+)-3-[4-(1- piperidinoethoxy)pnenyl]spiro[indene-1,1′-indane]-5,5′-diol hydrochloride: a promising nonsteroidal estrogen receptor agonist for hot flush. J. Med. Chem. 2003, 46, 3961-3964.
11. Grese, T. A.; Pennington, L. D.; Sluka, J. P.; Adrian, M. D.; Cole, H. W.; Fuson, T. R.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Shetler, P. K.; Short, L. L.; Venugopalan, M.; Yang, N. N.; Sato, M.; Glasebrook, A. L.; Bryant, H. U. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J. Med. Chem. 1998, 41, 1272-1283.
12. Corey, E. J.; Helal, C. J. Reduction of carbonyl compounds with chiral oxazaborolidine catalysts: a new paradigm for enantioselective catalysis and a powerful new synthetic method. Angew. Chem., Intl. Ed. 1998, 37, 1986.
13. The absolute configuration was assigned based on an X-ray crystal structure of 1 bound to ERα.
14. For a detailed description of the ER binding and MCF-7 assay protocols, see: Wallace, O. B.; Lauwers, K. S.; Jones, S. A.; Dodge, J. A. Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs). Bioorg. Med. Chem. Lett. 2003, 13, 1907-1910.
15. For a detailed description of the Ishikawa assay protocol, see: Wallace, O. B.; Bryant, H. U.; Shetler, P. K.; Adrian, M. D.; Geiser, A. G. Benzothiophene and naphthalene derived constrained SERMs. Bioorg. Med. Chem. Lett. 2004, 14, 5103-5106.
16. Lyttle, C. R.; DeSombre, E. R. Uterine peroxidase as a marker for estrogen action. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 3162-3166.
17. Kym P. R.; Anstead G. M.; Pinney K. G.; Wilson, S. R.; Katzenellenbogen J. A. Molecular structures, conformational analysis, and preferential modes of binding of 3-aroyl-2-arylbenzo[b]thiophene estrogen receptor ligands: LY117018 and aryl azide photoaffinity labeling analogues. J. Med. Chem. 1993, 36, 3910-3922.
18. (b) Li, X.; Takahashi, M.; Kushida, K.; Inoue, T. The preventive and interventional effects of raloxifene analogue (LY117018 HCl) on osteopenia in ovariectomized rats. J. Bone Min. Res. 1998,13, 1005-1010.
19. (c) Curiel, M. D.; Calero, J. A.; Guerrero, R.; Gala, J.; Gazapo, R.; De La Piedra, C. Effects of LY-117018-HCl on bone remodeling and mineral density in the oophorectomized rat. Am. J. Obst. Gynecol. 1998, 178, 320-325.
20. (d) Jones, C. D.; Jevnikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2- (1-piperidinyl)ethoxy]-phenyl]-methanone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 1984, 27, 1057-1066.
21. (e) Wakeling, A. E.; O'Connor, K. M.; Newboult, E. Comparison of the biological effects of tamoxifen and a new antiestrogen (LY 117018) on the immature rat uterus. J. Endocrinol. 1983, 99, 447-453.
22. Simpkins, J. W.; Katovich, M. J.; Song, I.-C. Similarities between morphine withdrawal in the rat and the menopausal hot flush. Life Sci. 1983, 32, 1957-1966.
23. (b) Merchenthaler, I.; Funkhouser, J. M.; Carver, J. M.; Lundeen, S. G.; Ghosh, K.; Winneker, R. C. The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas 1998, 30, 307-316.
24. (c) Komm, B. S.; Lyttle, C. R. Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann. NY Acad. Sci. 2001, 949, 317-326.